•
Dec 31, 2019

Chemours Q4 2019 Earnings Report

Chemours' Q4 2019 results reflected a challenging year with solid fourth-quarter performance.

Key Takeaways

Chemours reported Q4 2019 net sales of $1.4 billion and a net loss of $(317) million, or $(1.94) per diluted share. Adjusted net income was $92 million, or $0.56 per diluted share, and adjusted EBITDA was $227 million. The company finished the year strong with $304 million in free cash flow.

Net sales were $1.4 billion.

Net loss was $(317) million, with EPS of $(1.94).

Adjusted net income was $92 million, with adjusted EPS of $0.56.

Free cash flow was $304 million.

Total Revenue
$1.35B
Previous year: $1.46B
-7.6%
EPS
$0.56
Previous year: $1.05
-46.7%
Gross Profit
$150M
Previous year: $400M
-62.5%
Cash and Equivalents
$943M
Previous year: $1.2B
-21.5%
Free Cash Flow
$304M
Previous year: $105M
+189.5%
Total Assets
$7.26B
Previous year: $7.36B
-1.4%

Chemours

Chemours

Forward Guidance

The company expects to deliver 2020 Adjusted EBITDA within a range of $1.05 to $1.25 billion, capital expenditures of approximately $400 million, and Free Cash Flow of greater than $350 million. The company expects to deliver Adjusted EPS of between $2.60 and $3.55 per share.

Positive Outlook

  • Top line growth across all segments.
  • Bottom line growth across all segments.
  • Significant improvement in free cash flow.

Challenges Ahead

  • Macroeconomic environment remains uncertain.